Thymopeptide Enteric-Coated Capsules Application Scope

Thymopeptide enteric-coated capsules can regulate and enhance the cellular immune function of the human body.

Immune-Related Diseases:

Chronic Hepatitis B (Adult): Suitable for chronic hepatitis B patients over 18 years old. After this age, thymus atrophy leads to decreased cellular immune function.
T-Cell Deficiency Diseases (Primary/Secondary): A treatment option for various primary or secondary T-cell deficiency disorders.
Autoimmune Diseases: Can be used for specific autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.
Cellular Immune Deficiency Diseases: Acts on various cellular immune deficiency pathologies.

Oncology Diseases Therapy: Serves as an adjuvant treatment for tumours, enhancing the body’s immunity to anti-cancers.

Thymopeptide Enteric-Coated Capsules Characteristics

Ingredients: A bioactive peptide extracted from bovine thymus with a molecular weight of less than 10,000 daltons, laying the foundation for its immunomodulatory function.
Properties: An enteric capsule formulation with off-white powder or granules as the content ensures drug release at specific intestinal sites.

Specification: 5 mg per unit, dictating the precise dosage form.
Packaging Specification: 24 units of 5 mg each, determining the quantity per package for convenient dispensing and storage.
Storage: Maintain in a sealed state to preserve drug integrity and stability.
Expiry Date: 36 months, indicating the duration within which the drug retains its potency and safety profile.
Executive Standard: WS1-(X-309)-2003Z, ensuring compliance with manufacturing and quality norms.
Approval Number: National Drug License H19991132, signifying regulatory authorization.
Date of Revision: October 22, 2009, marking the last update to the drug’s documentation.
Manufacturer: Enterprise name: Shanghai Baolong Pharmaceutical Co. (Abbreviated as Baolong Pharmaceutical), responsible for the drug’s production and quality control.

Guidelines For The Use Of Thymopeptide Enteric-Coated Capsules

Dosage and Administration: Oral administration: 2 – 5 tablets each time, 3 times a day. Adjust flexibly according to the doctor’s advice to ensure accurate dosing.

Adverse Reactions: Generally well-tolerated, but some patients may experience nausea, fever, dizziness, chest tightness, weakness, and occasional drowsiness. In chronic hepatitis B patients, a transient increase in ALT level may occur. Treatment can continue if there is no sign of liver failure, providing a basis for medication monitoring.

Medication Limitations

Contraindications: Contraindicated in patients allergic to this drug and organ transplant recipients, strictly excluding high-risk populations.

Precautions:

Its immune-enhancing property determines its prohibition in patients undergoing immunosuppressive therapy (unless benefits outweigh risks) to prevent immune imbalance risks.
Regularly monitor liver function during treatment to monitor the impact on liver metabolism.
Use with caution in patients under 18 years old, carefully weighing the pros and cons of pediatric medication.

Thymopeptide Enteric-Coated Capsules Interactions

Compatibility with Common Drugs: When combined with numerous frequently used drugs such as interferon, anti-inflammatory agents, antimicrobials, hormones, analgesics, antihypertensives, diuretics, cardiovascular drugs, central nervous system medications, and contraceptives, no interference occurs.
Synergistic Effect with Interferon: In combination with interferon, it exhibits a synergistic impact on enhancing immune function.

More instruction about Thymopeptide Enteric-Coated Capsules to check how to take Thymopeptide Enteric-Coated Capsules

Note: If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYueMed. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.